

**Patient Information:**

- **Name:** Gerald Francis Halvorsen
- **Patient ID:** SYN059
- **DOB:** 26/04/1950 (Age at death: 71)
- **Gender:** Male
- **Date of Diagnosis:** 18/10/2019
- **Primary Diagnosis:** WT NSCLC with brain metastases

**Molecular Profile:**

- **Driver Mutation:** WT (NGS negative)
- **PD-L1 Status:** TPS <1%, CPS 6, IC 0 (22C3)

**Treatment Course:**

- **First-Line Therapy:** Carboplatin + Pemetrexed + Pembrolizumab 08/11/2019 until June 2020
- **Second-Line Therapy:** Ramucirumab since 18/06/2020

**Clinical Course:** Mr. Halvorsen presented with dizziness and vision changes. MRI revealed three parietal lobe lesions. Systemic therapy began with rapid symptom improvement. By month 6, CNS progression necessitated WBRT. Systemic disease worsened concurrently, prompting 2L docetaxel, which was poorly tolerated. Hospice initiated February 2021.

**Date of Death:** 14/02/2021 **Cause of Death:** Intracranial progression and neurologic decline